Russell Alan J
Chief Scientific Officer
Russell Alan J has filed 3 SEC Form 4 filings (11 transaction rows) across 1 company, with disclosures dating back to 2025. 3 of those filings fall inside the rolling window. Most recent filing: Aug 14, 2026.
On the most recent filing, Russell Alan J is listed as Chief Scientific Officer at Edgewise Therapeutics, Inc. Inside the rolling window, Russell Alan J reported no open-market purchases and 3 open-market sales totaling $10.3M in EWTX. The largest disclosed transaction in the window is a sale of 200,000 EWTX shares on Jul 1, 2026, worth $7.9M.
Companies traded
Other insiders at EWTX
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$10.3M
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has Russell Alan J made?
Russell Alan J has filed 3 SEC Form 4 filings (11 transaction rows) across 1 company since 2025.
Which companies does Russell Alan J trade?
Russell Alan J has filed SEC Form 4 disclosures for 1 company, including EWTX.
When was Russell Alan J's most recent SEC Form 4 filing?
Russell Alan J's most recent SEC Form 4 filing on Tracefour is dated Aug 14, 2026.
What is Russell Alan J's job title?
On the most recent SEC Form 4 filings tracked by Tracefour, Russell Alan J is listed as Chief Scientific Officer.
What is Russell Alan J's total buy and sell value in the current window?
Inside the rolling retention window, Russell Alan J bought $0 and sold $10.3M based on SEC Form 4 filings.
What was Russell Alan J's largest disclosed transaction?
The largest disclosed transaction in the current window is a sale of 200,000 EWTX shares on 2026-07-01, worth $7.9M, per SEC Form 4 filings.